Cefiderocol Sulfate Tosylate (1 brand name, 1 dosage form, 1 route)
Available dosage forms: POWDER.
Routes of administration: INTRAVENOUS.
Brand Names
- FETROJA
Contraindications
FETROJA is contraindicated in patients with a known history of severe hypersensitivity to cefiderocol or other beta-lactam antibacterial drugs, or any other component of FETROJA [see Warnings and Precautions (5.2)and Adverse Reactions (6.1)] .
Adverse Reactions
The following serious adverse reactions are described in greater detail in the Warnings and Precautions section: Increase in All-Cause Mortality in Patients with Carbapenem-Resistant Gram-Negative Bacterial Infections [see Warnings and Precautions (5.1)] Hypersensitivity Reactions [see Warnings and Precautions (5.2)] Clostridioides difficile-associated Diarrhea (CDAD) [see Warnings and Precautions (5.3)] Seizures and Other Central Nervous System Adverse Reactions [see Warnings and Precautions (5.4)]
Mechanism of Action
FETROJA is an antibacterial drug [see Microbiology (12.4)] .
Overdosage
There is no information on clinical signs and symptoms associated with an overdose of FETROJA. Patients who receive doses greater than the recommended dose regimen and have unexpected adverse reactions possibly associated with FETROJA should be carefully observed and given supportive treatment, and discontinuation or interruption of treatment should be considered. Approximately 60% of cefiderocol is removed by a 3- to 4-hour hemodialysis session [see Clinical Pharmacology (12.3)].